AN2 Therapeutics, Inc.ANTXNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank33
3Y CAGR-5.7%
5Y CAGR+32.7%
Year-over-Year Change
Research and development spending
3Y CAGR
-5.7%/yr
Annual compound
5Y CAGR
+32.7%/yr
Recent deceleration
Percentile
P33
Within normal range
vs 5Y Ago
4.1x
Strong expansion
Streak
2 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $24.77M | -38.8% |
| 2024 | $40.49M | -26.2% |
| 2023 | $54.87M | +85.9% |
| 2022 | $29.51M | +74.6% |
| 2021 | $16.91M | +180.9% |
| 2020 | $6.02M | -79.5% |
| 2019 | $29.33M | - |